ya know, you're sooooo full of yourself and your BS comments. When Cypher was the only thing entering the market, you were JNJ all the way. What are you? A sissy???? Jeaz, I would guess you could hold you allegance through good and bad. JNJ sucks and they always will. Too big, too egocentric, too full of themselves.
I'll give you credit for staying under your rock until you could slither out at this opportune time to shout more of your venom against Cordis and J&J.
J&J has been around for over 100 years, and will outlive both of us as it continues to prosper as a great corporation.
The battle of the stent wars has just begun.
let us not make such a big deal over this.
JNJ stents are only a small portion of total revenues. For BSX it is tantamount that their stents do well.
Heck, over 50% of JNJ's revenues are consumer.
Consumer doesn't count for sh$t. Don't pay attention to the revenue line - how many times does your finance teacher have to tell you that? Free Cash Flow! Those stents have big fat margins on them while the consumer revenue does not. (Same with the pharma group - fat margins). The revenue from those stents will grow quickly but it's the earnings and cash flow from those babies that you need to look at.
My belief is that doctors will look at the pricing since none of the data is a slam dunk yet. If there is a pricing war nobody wins. However, I will conisder shorting BSX since 75% of their future growth multiple rests in those stents and if there is a price war, they will have some issues.